InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,715.21
(
0.22%
)
US TECH 100
19,324.80
(
0.14%
)
Dow Jones
42,101.55
(
0.09%
)
Brent Oil
73.41
(
-0.65%
)
Bitcoin
63,446.42
(
-0.28%
)
Post# of 658986
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Volcano

Send PM Follow Ignore
Followers 495
Posts 32172
Boards Moderated 0
Alias Born 03/12/2014

Volcano

Re: None

Tuesday, 06/21/2022 9:33:27 AM

Tuesday, June 21, 2022 9:33:27 AM

Post# of 658986
Big news coming this week!
Fasten your seat belt

Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
Mentioned: CAPR
EQNX::TICKER_START (NASDAQ:CAPR), EQNX::TICKER_END Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that the Company will present one-year, safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD) at this year's Parent Project Muscular Dystrophy (PPMD) Annual Conference.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up